TIDMAVG
RNS Number : 7517C
Avingtrans PLC
03 October 2018
3 October 2018
Avingtrans plc
("Avingtrans" or the "Group")
Preliminary Results for the year ended 31 May 2018
Avingtrans plc, which designs, manufactures and supplies
critical components, modules, systems and associated services to
the energy, medical and industrial sectors, is pleased to announce
its preliminary results for the twelve months ended 31 May 2018.
The results include nine months contribution from Hayward Tyler
Group ("HTG"), the acquisition of which was completed on 1
September 2017. The Board is pleased to report that the integration
of the HTG business has gone well and has now completed, ahead of
schedule; further proof of the Group's Pinpoint-Invest-Exit ("PIE")
strategy in action.
Financial Highlights
-- Revenue increased by 247% to GBP78.9m (2017: GBP22.7m), driven by HTG acquisition
-- Underlying revenue growth, excluding acquisitions was 10.9%
-- Improved Gross Margins at 25.5% (2017: 17.9%)
-- Adjusted EBITDA increased by 690%, to GBP5.7m (2017: GBP0.7m)
-- Adjusted Profit before Tax increased by 820%, to GBP2.4m (2017: GBP0.3m)
-- Adjusted Diluted earnings per share increased to 8.4p (2017: 1.1p)
-- Cash outflow from operating activities GBP6.9m (2017: GBP3.3m)
-- Net Debt was GBP7.1m (31 May 2017: net cash of GBP26.4m)
-- Increased final dividend of 2.3p per share (2017: 2.2p). Full year 3.6p (2017: 3.4p)
Operational Highlights
Energy
-- Revenues up to GBP68.4m (2017: GBP12.6m) driven by the HTG acquisition
-- Restructuring and integration of HTG complete
-- Ormandy acquisition completed for GBP0.1m. Integration proceeding to plan
-- Sellafield pre-production phase completed. Now moving into ramp-up phase
-- Prestigious award for SME skills investment at Metalcraft
Medical
-- Revenues broadly flat at GBP10.4m (2017: GBP10.1m), transitioning to new markets
-- Siemens shipments remained steady in the UK and China
-- Scientific Magnetics secured first service contracts with partner MR Resources Inc.
-- Expansion of relationship with QOne NMR Instruments in Wuhan, China
-- Rapiscan relationship with Composite Products continues to build positively
Post Period-End Highlights
-- GBP5m UK government contract won by Peter Brotherhood
-- DOE Funding secured for innovative renewable solar technologies
Commenting on the results, Roger McDowell, Chairman, said:
"It has been an exciting year, during which, the Group continued
to execute its Pinpoint-Invest-Exit strategy (PIE) through the
acquisitions of Hayward Tyler Group (HTG) and also Ormandy Group.
With an eye on eventual exits, we have restructured the Group into
two separate energy divisions and an incubator medical division. A
highlight of FY2018 was the speedy and successful integration of
the substantial Hayward Tyler Group acquisition. The new Energy
divisional structures and management teams have become effective
quickly and their focus is clearly on growth, to build two
formidable and valuable divisions. The nascent medical division
made slower progress, though we have galvanised our strategic path
by partnering on service with MR Resources Inc.
We are nurturing an unswerving focus on aftermarket
opportunities, as we service end-user customers with fast, local
and flexible solutions, resulting in strong growth prospects.
Nuclear life extension and decommissioning markets also continue to
provide fertile ground for growth, underpinned by contract wins in
the UK, USA, South Korea and mainland Europe. However, we are
mindful of avoiding over-dependence on nuclear and thus, we are
developing into new markets, such as renewables with (eg) funding
from the DoE in the USA for future generation solar plants.
Exciting times lie ahead."
Enquiries:
Avingtrans plc 01354 692391
Roger McDowell, Chairman
Steve McQuillan, Chief Executive Officer
Stephen King, Chief Financial Officer
N+1 Singer (Nominated Adviser) 02074 963000
Shaun Dobson
Lauren Kettle
Newgate (Financial PR) 02076 539850
Adam Lloyd
Tom Carnegie
About Avingtrans plc:
Avingtrans is engaged in the provision of highly engineered
components, systems and services to the energy, medical and traffic
management industries worldwide.
Energy and Medical
Stainless Metalcraft Ltd - Chatteris, UK and Chengdu, China
Provider of safety-critical equipment for the energy, medical,
science and research communities, worldwide, specialising in precision
pressure and vacuum vessels and associated fabrications, sub-assemblies
and systems. Maloney Metalcraft Ltd - Aldridge, UK
Designs, manufactures and services oil and gas extraction and processing
equipment, including process plant for dehydration, sweetening,
drying and compression. Hayward Tyler - Luton & East Kilbride,
UK and USA, China and India Specialises in the design, manufacture
and servicing of performance-critical motors and pumps in challenging
environments. Peter Brotherhood - Peterborough, UK Specialises
in the design, manufacture and servicing of performance-critical
steam turbines, turbo gen-sets, compressors, gear boxes and combined
heat and power systems.
Composite Products Ltd - Buckingham, UK Centre for composite technology,
parts and assemblies, serving customers in industrial markets.
Scientific Magnetics - Abingdon, UK Designs and manufactures superconducting
magnet systems and associated cryogenic systems for a variety of
markets. Crown International Ltd - Portishead, UK Designs and manufactures
market-leading pole and support systems for roadside signage and
safety cameras, rail track signalling and gantries.
Chairman's Statement
In an exciting year of execution and delivery for Avingtrans, it
is pleasing to report an improved overall performance for FY2018,
which saw significant acquisition activity and investment as the
Group continued to execute its Pinpoint-Invest-Exit strategy
(PIE).
The main highlight of our financial year was the successful
integration of the substantial Hayward Tyler Group (HTG)
acquisition, completed ahead of schedule. The Board are pleased to
report that in integrating HTG, it has been able to achieve its
targeted cost savings and the combined businesses are demonstrating
the anticipated synergies, with an invigorated combined sales force
and operational efficiencies. Avingtrans also completed the
acquisition of the assets of Ormandy Group in the year; a leading
provider of offsite heat exchange solutions, which now forms part
of the Maloney Metalcraft business.
With one eye on eventual exits, we have restructured the Group
into two separate energy divisions and an incubator medical
division; Process Solutions and Rotating Equipment (PSRE),
Engineered Pumps and Motors (EPM) and Medical and Industrial
Imaging (MII).
The new Energy divisional structures and management teams have
become effective in short order and with two solid platforms
displaying good global reach, product and service diversity, their
focus is now clearly on growing into formidable and valuable
businesses.
From Avingtrans' existing assets and the Board's ongoing
strategy of shrewd acquisitions, the Group has laid the foundations
to create a new medical and industrial imaging division, which
promises to produce a unique market offering.
Common across all three divisions is a strategic aim to develop
robust value propositions, including aftermarket services to
support OEM and end-user customers, who are either operating Group
products or systems, or who have operational problems that the
Group can solve with its combined capabilities. This improved
end-user model not only drives profitability and gives a more
predictable and repeatable pipeline, but also boosts product and
service development and innovation, given the deep knowledge of
customer risks and issues that is developed. We are particularly
keen to maximise the revenue opportunities arising from the
aftermarket access afforded by recent acquisitions and
partnerships.
The Process Solutions and Rotating Equipment (PSRE) division
recently added the assets of Ormandy to its portfolio and in
parallel is continuing to refine its offering to the UK nuclear
decommissioning market - especially to Sellafield - whilst also
using this capability to position for longer term new nuclear
technologies.
The Engineered Pumps and Motors (EPM) division bolstered its
capability in India with a new motor rewind centre and has now
opened a new 4000 square metres facility in Kunshan, China. Both of
these enhanced capabilities will help secure the end-user business
in the region, including the valuable aftermarket. These facilities
also act as operational hubs for the sale of original equipment,
cost effective sourcing, engineering and tendering, as the shift
for EPM to become a seamless global operation takes shape. We are
also considering the options to maximise the site utilisation at
Luton, UK, given this evolving strategy.
The Medical and Industrial Imaging (MII) division continues to
show modest revenue growth, with both the UK and Chinese businesses
establishing their positions in the supply chain. As the new
equipment business develops into growing niche markets, the
addition of Scientific Magnetics Ltd and the MR Resources Inc.
pan-European partnership - to bring Nuclear Magnetic Resonance
(NMR) system support, servicing and service contracts to European
NMR users - will underpin the significant investment in this
division.
For the seventh successive year, the Board has declared an
increased final dividend of 2.3 pence per share, producing a full
year total of 3.6 pence per share, underlining our commitment to
long term shareholder returns and our positive view about the short
and longer-term prospects for the Group.
Finally, during the year, Ewan Lloyd-Baker (formerly CEO, HTG)
and John Clarke (formerly CEO of the Nuclear Decommissioning
Authority) joined the Board as NEDs. I warmly welcome them and all
of the HTG and Ormandy staff to Avingtrans. Their passionate and
energetic efforts to create world class engineering enterprises
will enrich the Group. On behalf of the shareholders, I thank them
and all Avingtrans employees for their hard work and commitment to
the Group during the past 12 months, as we look forward with relish
to FY2019.
Roger McDowell
Chairman
2 October 2018
Strategy and business review
Group Performance
Group Strategy
Our core strategy is to buy and build engineering companies in
niche markets where we see consolidation opportunities; a strategy
we call Pinpoint-Invest-Exit ("PIE"). We have had a strong track
record in returning significant shareholder value over the past
decade and 2018 was another successful year; further demonstrable
proof of execution and transition into the global energy space
through the successful acquisition and effective integration of the
HTG business.
With an increased presence in the market place, strength in
depth of the management team and a lean central structure with a
focus on its divisions, the Group is poised to continue this growth
and the Board has renewed its focus on seeking valuable additions
to the Avingtrans proposition.
All of the Group's key financial metrics showing positive growth
in what continued to be challenging market conditions in some areas
(e.g. Oil and Gas) and despite a period of restructuring for the
Group; the successful and swift integration of HTG was executed
efficiently and effectively.
The three new divisions are fully operational and the business
is focused on the global Energy and Medical markets. Both of these
markets play into some of the world's mega-trends, including
continued urbanisation and general prosperity, an ageing population
and a transition towards a cleaner and healthier planet. For
example, world GDP is expected to more than double by 2040, driven
by increasing prosperity in emerging economies, as more than 2.5
billion people are lifted from low incomes.
Divisional Strategies
Engineered Pumps and Motors (EPM, Energy): EPM continues to
develop its nuclear installed base (civil and defence) - notably
for life extension applications - and its offering to the fossil
fuels market sectors. In addition, the EPM business is developing
solutions for new nuclear technologies and other low carbon energy
sources, concentrated solar for example, to capitalise on the
global energy supply transition.
Process Solutions and Rotating Equipment (PSRE, Energy): The
primary strategy is developing a comprehensive offering to the
nuclear decommissioning and reprocessing markets, building on the
long-term contracts to build nuclear waste storage containers and
the installed base of equipment across the vast Sellafield site. In
parallel, continuing to support the nuclear submarine fleet and
facilities for the UK MOD and targeted opportunities in the equally
highly regulated offshore Oil & Gas markets.
Medical and Industrial Imaging (MII, Medical): The focus for the
medical division is to become a niche market leader in the
production of high integrity components and systems for medical and
scientific equipment manufacturers including MRI, proton therapy
and Nuclear Magnetic Resonance (NMR).
One common theme we are looking to exploit across energy and
medical, is the continued pressure on aftermarket expenditure,
especially in OECD countries, where operational efficiency,
reliability and safety are paramount and operators are looking to
their supply chain partners to provide long term support of aging
infrastructure and legacy installations. Connecting with end-users
and understanding and solving operational problems for the present
and the future has the added benefit of focusing the front end
development work on products and services that strengthen the
Group's position as a through-life / aftermarket partner in its
chosen end markets.
As energy capital goods markets continue to recover, M&A
activity remains strong and businesses like ours are commanding
high valuations. Avingtrans remains confident about the current
strategic direction and potential future opportunities across all
of its chosen markets.
Markets - Energy
The global demand for energy continues to rise steadily, driven
primarily by population increase and continued urbanisation and
improved prosperity. In the longer term, the latest estimates show
that overall demand may slow, due to increased efficiency and
decarbonisation, but for the time being the global energy compound
annual growth rate (CAGR) can be assumed to be of the order of
2%.
The energy market can be dissected by use, by region and by fuel
with some general observations as follows:
-- End Use - industry remains the prime user with over 50%
demand, the other 50% is split mostly between transport and
buildings, with transport seeing a slight future reduction due
mainly to efficiencies and vehicle electrification.
Markets - Energy (continued)
-- End Region - almost all of the growth in energy demand comes
from fast-growing developing economies. China, India and other
emerging Asian countries account for around two-thirds of the
growth.
-- Fuel Type - the energy mix by fuel continues to diversify,
with the fastest growing being renewables, but also with gas
growing faster than coal and oil. The transition is still slow
however and coal as a fuel for generating electricity will remain
the number one choice throughout the next decade, even though the
introduction of new plants is in long term decline.
End User/Aftermarket
As the overall energy landscape continues to evolve, the demand
for best in class through-life support to operators and end-users
continues to be paramount. Increasing mean time between failures,
improving the predictability of equipment performance and
increasing efficiency and ultimately operator and public safety are
consistent market drivers across all the energy markets.
Operators and end-users are demanding a blend of quick response
through local support with an overarching requirement to drive
improvements through equipment upgrades and modernisation. In the
West, where facilities are being operated for longer than their
intended design lives - and often a drive for increased capacity
alongside tougher regulations - there is a strong demand for true
solution providers in the supply chain to partner with end-users
for the longer term.
The Avingtrans energy divisions are well positioned to grow in
this end-user market space. With increased relevance and global
reach, balanced alongside heritage and renowned expertise, they can
find niche positions and value propositions alongside the huge
global players and the local independents.
Nuclear
Nuclear energy as a low carbon, baseload power source for the
future remains an uncertain market place with respect to future
growth. Almost all the 1GW+ new build opportunities are currently
in Asia, with the exception of the UK programme, and as the market
develops the Asian developers, alongside the Russians, with their
ability to fund projects, are dominating this section of the
market.
However, we still foresee buoyant market segments supporting the
operational fleet, continued safe operation and life extensions,
the back end of the fuel cycle, decommissioning and reprocessing,
and the development of the next generation of technologies ie Small
Modular (SMR) or Advanced Generation IV Reactors. In addition they
all have the backdrop of a dwindling supply chain and expert
knowledge which plays directly to the Avingtrans capability.
The USA still operates the biggest civil nuclear fleet in the
world, 99 reactors generating more than 30% of the world's nuclear
electricity. When coupled with the heritage Westinghouse technology
operating in Europe and Asia, the EPM division's long standing
position in this market place is fertile ground for further growth.
Obsolescence is a key issue globally for nuclear operators and the
Avingtrans Energy Divisions are well positioned to support
operators with this key operational issue.
The UK remains dominant when it comes to decommissioning and
reprocessing, both in terms of innovative technology and overall
spend. The Group is embedded in the future manufacture of waste
containers for Sellafield and with an installed base and experience
across this market, will continue to expand its presence in the UK
and globally in the longer term.
The development of new nuclear technologies is ongoing, with
pockets of development in the USA, UK, China, Russia and South
Korea. The USA and China are dominating activity and the Group
views these new technologies as an attractive route forwards for
nuclear and, with its increased presence and product offering, is
positioned well to develop as an industry partner.
Power Generation
The world continues to electrify, with an ever increasing amount
of primary energy going to the power sector which remains a key
focus across the Group's energy divisions. Aside nuclear, discussed
in the previous section, the main sub-sectors are as follows:
-- Coal - The Group continues to see good aftermarket from coal
fired power stations even though the demand for new power stations
is in decline. Opportunities still exist in India, China, South
East Asia, Eastern Europe and the Middle East and EPM is optimising
its product line to take market share and to create tomorrow's
aftermarket.
Markets - Energy (continued)
-- Gas - Natural gas, primarily in the form of combined cycle
gas turbine power plants is a growing market space, primarily in
the West. Still not dominated by Asian EPCs and equipment
suppliers, the Group is moving into this market space with both
existing and new product lines.
-- Renewables - renewable technologies and their supporting
infrastructure are a growing market globally. The Group has a broad
range of products that can be applied directly to this market and
also expertise that can be used to develop new products for niche
parts of this market such as molten salt for concentrated solar
applications. With biomass and waste to energy being developed
slowly in Europe and concentrated solar being driven by China and
the USA, the Group is well positioned to exploit this growing
market from across its entire energy portfolio.
Oil & Gas
After several years of oversupply, the industry feels much
healthier than it did 12 months ago and the price of oil has
rebounded with Brent crude now trading above $70 a barrel. The
industry is recovering from the recent years of weak prices, low
capital expenditure, portfolio realignments, and productivity
efficiencies and the effect is starting to be seen across the Oil
& Gas sector.
-- Upstream - Investment in exploration is now increasing 6%
year on year, which although still only half what it was at the
beginning of the decade, marks a massive change over recent years.
Operating expenditure is now being released to secure current
operations, resulting in capex beginning to be slowly released for
major new projects. The Group is witnessing the front end of this
activity through increased bidding and is optimistic regarding
future projects. The ongoing investments in disruptive technologies
such as the subsea boosting technology from F-Subsea that EPM is an
exclusive partner to, are now poised to move through the
development phase to full deployment, as the market reopens.
-- Midstream - The longer term midstream trend of interest to
the Group, is the evolving liquefied natural gas (LNG) market, for
which there is a growing demand and a continual import export
transition developing. However, although the market predictions for
FLNG and FRSU vessels remain bullish, in reality activity in the
supply chain remains stagnant. The Group maintains a close eye on
developments and supports projects at the appropriate level from
early engineering ("FEED") studies. Timing remains challenging, but
the Group is confident of securing some projects.
-- Downstream - Slower growth in liquids demand combined with
continued growth of LNG and biofuels continues to put pressure on
global refining. New refinery projects which are already planned or
under construction for the next five years are judged to be
sufficient to meet new capacity. However, the Group's equipment is
installed in critical systems on existing plants where continued
operation is key, so aftermarket opportunities are strong. In some
cases, such as the UK, where the supply chain companies are
reducing in number, the Group is well positioned to adopt long term
service partnerships across a range of systems and rotating
equipment.
Digitalisation
Companies across the energy market continue to invest in digital
technologies to improve productivity, efficiency and predictability
in the field. At equipment level this translates to a series of
devices, sensors and databases that can both predict breakdowns
before they occur and ensure equipment is running at its optimum
performance. The Group has successfully launched its first
monitoring product, DataHawkTM, for Boiler Circulating Pumps and
will build off this success to add this capability to both a wider
set of original equipment and its aftermarket service offering.
Markets - Medical
The Diagnostic (medical) and molecular imaging markets are large
global sectors, dominated by a few large systems manufacturers. The
total Diagnostic Imaging Market is c$34bn (2016) and expected to
grow at 5% per annum over the next 10 years.
The largest market is the USA (25%), followed by Europe (19%)
and Japan (17%). China (12%) and India (3%) are the fastest growing
markets. Three companies (Siemens, GE and Philips) account for an
estimated 78% of revenue in the market.
The Avingtrans medical division is primarily targeting the
Magnetic Resonance Imaging (MRI) and Nuclear Magnetic Resonance
(NMR) segments of these markets, due to the common thread
requirements for superconducting magnets and cryogenics. These two
segments account for approximately 85% of our business in the
medical division. Market drivers for these segments include ageing
populations worldwide and the global pharmaceutical industry's
research needs. MRI is approximately 16% by value of the total
diagnostic Imaging market and projected to grow at 5% p.a. NMR is a
smaller market, currently estimated at $650m p.a. and growing also
at 5% p.a, with Bruker enjoying a current market share of over
80%.
Markets - Medical (continued)
End User/Aftermarket
The MRI market segment is dominated by a handful of global
manufacturers, including GE, Siemens and Philips. These players
also dominate the aftermarket, though there are a few independent
MRI service businesses in existence. Avingtrans is not present in
the MRI aftermarket at this time.
The NMR market is similar, currently dominated by Bruker (CH/DE)
and Jeol (JA). Avingtrans is now closely aligned MR Resources Inc,
a well-established US business, which services the NMR aftermarket.
The Avingtrans medical division is well positioned in this end-user
market space and has now started to win service contracts with
European NMR users, following our recent partnership agreement with
MR Resources.
MRI
As noted above, the MRI market segment is dominated by a handful
of global manufacturers. For component and sub-system supply,
Avingtrans is most aligned to the market leader, Siemens and also
to Canon, which acquired the Toshiba MRI business in recent years.
As far as full system supply is concerned, we are currently
investigating a number of niche MRI applications (eg veterinary
imaging) and their associated routes to market, with the intention
of pinpointing the most promising of these for future
investment.
NMR
The previous attempts by Avingtrans to align with the market
leader Bruker were unfruitful, so we have pivoted to align with new
market entrant Q One Instruments of Wuhan, China and also with MR
Resources of the USA, as noted above. Together, we form an alliance
to challenge the dominance of the existing players and to provide
the customers with an additional source for NMR products, service
and support. Former NMR customers of Agilent (formerly Varian) are
also being given much needed support. Whilst early days for this
initiative, we are already seeing success in winning support
contracts for end users and the prospect list for Q One Instruments
is promising.
Operations
The two energy divisions are now fully restructured and the
necessary right-sizing of both Hayward Tyler and Peter Brotherhood
was completed quickly and effectively, being assisted by a common
IT platform.
Operational Key Performance Indicators (KPIs)
2018 2017
* Customer Quality - defect free deliveries (%) 97.3 99.2
* Customer on time in-full deliveries (%) 84.2 99.7
* Annualised staff turnover including restructuring (%) 17.3 10.2
* Health, Safety and Environmental incidents per head
per annum 0.14 0.13
Customer quality and on-time deliveries were adversely affected
this year - mainly due to lower performance in HTG, which was
struggling with deliveries, as a result of cash flow issues and a
resulting creditor overhang. These statistics have been gradually
improving since the acquisition. Staff turnover was also impacted
by the substantial restructuring of HTG in the period. Pleasingly,
HSE statistics were similar between the businesses.
EPM Division - Energy
The EPM division, which represents the bulk of the legacy
Hayward Tyler companies (excluding East Kilbride) has an enviable
installed base across the globe and strong brand recognition.
Coupled with its strong domain knowledge across the energy market
and its core competencies in wet wound electrical motors, canned
motor pumps and nuclear codes and standards, the division continues
to expand its end-user offering.
The division finds itself in a relatively strong position, since
it is more agile than some of its bigger competitors, has a
respected OEM brand unlike the local independents and is able to
offer a strong solution-based offering for its own installed base
as well as other Original Equipment Manufacturers.
With a fully developed presence in Europe and North America, the
division has now completed the opening of its delayed new China
facility and the new motor rewind centre in India. The integration
of these regional centres alongside other regional partners in key
territories will give the division expanded global reach,
capability and the platform to expand its end-user business.
Operations (continued)
In the UK, EPM has recently signed an Authorised Channel and
Service Partner agreement with Baker Hughes, a GE company (BHGE),
which has significant installed base in the UK, but no effective
local facility to service, overhaul and upgrade their equipment.
Customers are demanding a quicker, more local response and, between
EPM and BHGE, both respected but non-competing OEMs, this
partnership will provide both incremental growth and also a
template for other such opportunities around the world.
In addition to the drive for improved end-user business, EPM is
also addressing the shift towards a low carbon energy future. Its
experience and product knowledge have allowed it to gain its first
order from a Gen IV nuclear developer in the USA for a future
molten salt technology and also funding from the US Department of
Energy to develop molten salt pump technology for advanced
concentrated solar applications. With its new range of pumps and
its optimised seal-less circulating pumps for natural gas and a
range of renewable technologies, EPM is slowly but surely reducing
its reliance on coal fired power stations.
PSRE Division - Energy
Following the roll out of the new divisional structure, PSRE
acquired the trade and assets of Ormandy Ltd for GBP0.1m. The
Ormandy Group manufactures off-site plant, heat exchangers and
other HVAC (heating, ventilation and air conditioning) products and
the synergies that exist between the Ormandy Group and the PSRE
businesses will allow Ormandy to re-establish its presence in an
improving market space.
The Hayward Tyler fluid handling business in East Kilbride,
Scotland was moved into the PSRE division, to expand its capability
and capacity to support the nuclear decommissioning and
reprocessing market in the UK. This further strengthened the
division's strategic relationship with Sellafield Limited and the
Nuclear Decommissioning Authority. Given the addition of John
Clarke as a NED, this active market place clearly remains a key
focus for us.
In parallel to the end-of-fuel-cycle nuclear market above - and
with the addition of the Peter Brotherhood capability - the Group
also has a keen interest in both the UK nuclear submarine fleet and
associated facilities, as well as developing new nuclear
technologies like SMRs (Small Modular Reactors). The division has a
good installed base on the UK submarine fleet, is the chosen
manufacturing partner for the Astute steam turbines and through
this experience has the right capability, nuclear culture and
experience to support longer term nuclear technologies.
Away from nuclear, the divisional brands also have a strong
presence in the Oil and Gas market place through the likes of Peter
Brotherhood and Maloney Metalcraft. This market remains
challenging, but activity is increasing and with the global demand
for LNG still predicted to grow significantly, the Group is quietly
confident about future opportunities that play to its strengths in
high quality, highly engineered, highly regulated engineering
solutions.
Aligned with the overall Group strategy to focus on end-user
business, the division has seen an increase in the ratio of
end-user to OEM sales. In particular Peter Brotherhood saw
increased aftermarket sales across its installed base, including on
one occasion an entire replacement steam turbine. End user service
arrangements have been signed to gain better access to the
reciprocating compressor installed base and a refresh of the
channel partners and agents has been concluded, to allow complete
focus on this aspect of the business. The business has a
well-developed end-user value proposition and with improved agility
and customer relevance, is confident of further growth.
Finally, the Crown business remains a small but solid performer
in the division with new applications becoming apparent for its
"smart" pole solutions. The first of these was the previously won
contract for Fluor, for flame-detector masts. These masts are being
deployed in a large scale petrochemical plant, to improve overall
site safety.
MII - Medical Division
Strategic progress at Scientific Magnetics is promising, but the
expected resulting orders have been slower to materialise than
originally thought and this business made a loss for the year, as
anticipated at the half year. However, we have continued to invest
in the business for the longer term and, early in 2018, we launched
a Europe-wide Nuclear Magnetic Resonance (NMR) service and support
offering with our US partner, MR Resources Inc. This potentially
exciting development will only start to bear fruit in the current
financial year, but this new service offering means that all three
divisions now have access to a solid aftermarket revenue
stream.
Metalcraft UK's business with Siemens for MRI components
continues to be steady, but progress in China with other vacuum
vessel customers - e.g. Alltech - was somewhat slower in ramping up
and was behind plan overall for the year. Composite Products had a
solid year, with deliveries to Rapiscan improving steadily and
showing promise for next year. Other smaller accounts also
supported revenues at this unit and a return to profit.
Financial Performance
Key Performance Indicators
The Group uses a number of financial key performance indicators
to monitor the business, as set out below.
Revenue: HTG acquisition drives growth
Overall Group revenue increased to GBP78.9m (2017: GBP22.7m),
primarily driven by the effect of the HTG acquisition. Underlying
revenue growth, excluding acquisitions was 10.9%.
Gross margin was 25.5% (2017: 17.9%) helped by higher HTG gross
margin, whilst margins excluding HTG were slightly down at 15.2%,
due to completion of a few legacy loss-making contracts following
the Ormandy acquisition and underutilisation at Scientific
Magnetics, as it undergoes a transition to new markets.
Profit margin: results skewed positively by acquisition
effects
Adjusted EBITDA (note 2) increased by 690% to GBP5.7m (2017:
GBP0.7m) with HTG contributing GBP5.1m in the 9 months following
acquisition. Operating loss increased to GBP3.8m (2017: GBP0.5m)
mainly due to the significant HTG exceptional costs which were
incurred in the period, initially for the acquisitions (GBP1.6m),
subsequently for right-sizing and restructuring GBP1.7m and the
amortisation of intangibles from business combinations (GBP3.3m).
Of this GBP1.9m EBIT related to HTG (note 5) and GBP2.6m (note 1)
from central costs including the direct costs of the HTG
acquisition GBP1.5m (note 5).
Tax: potential US upside to come next year
The effective rate of taxation at Group level was a 0.3% tax
credit primarily due to a deferred tax credit arising from the
amortisation of business intangibles offsetting the US tax charge,
whereas FY17 was a 3.9% tax charge. Following the acquisition of
HTG, we have a US business historically paying 39% tax which
reduced to c.27% following the recent US announcements from January
2018. The effective tax charge for the Group is also impacted by
the non-allowable transaction costs in the current year and not
recognising all the trading tax losses in the UK. The tax position
will be aided in the coming years, not only through the reduced US
rate, but also as we utilise elements of the UK and China tax
losses.
Adjusted Earnings per Share (EPS):
Adjusted diluted earnings per share for continuing operations
improved to 8.4p (2017: 1.1p)
Funding and Liquidity: Net Debt post acquisition remains low
Net Debt was GBP7.1m (31 May 2017: Net cash: GBP26.4m). HTG's
higher cost debt (GBP11.5m) elements were repaid at acquisition and
a further GBP10.7m absorbed, with HTG costs of GBP3.7m also being
incurred and paid. During the period, GBP3m was removed from the
HTG creditor overhang at the time of acquisition, with further
right-sizing restructuring costs of GBP1.7m and Avingtrans
acquisition costs of GBP1.6m also being paid alongside a further
working capital investment of GBP4.4m, principally HTG post
acquisition. Following the acquisition of Ormandy, it has been
trading out a few remaining loss-making contracts and rebuilding
its business to be in a profitable position. However, this has
required a cash investment for working capital and initial
underutilisation, which has since improved. Notwithstanding this
significant cash investment in the acquisitions during the year,
the Directors consider the Group to have sufficient financial
resources to deliver its short term strategic objectives, and
maintain a strong relationship with its banking partners.
Interest increased due to the additional debt assumed for the
HTG acquisition. Additionally it includes exceptional costs of
GBP0.2m arising from the loss on derivatives and the unwinding of
discounting on the dilapidation provision.
Dividend: steady progress continues
The Board again proposes to underpin our progressive dividend
policy. We are pleased to be able to recommend an improved final
dividend of 2.3 pence per share (2017: 2.2 pence per share). We
intend to continue on this progressive path, subject to the outcome
of acquisition activities in the coming years. The dividend will be
paid on 7 December 2018, to shareholders on the register at 26
October 2018.
Acquisition: fair value review
The fair value of the assets and liabilities of the acquisitions
(note 5) were reviewed including as assessment of the carrying
value in use of the properties which resulted in an impairment of
the Luton facility of GBP4.5m.
People
At Board level, Ewan Lloyd-Baker was formally admitted to the
Board upon completion of the acquisition of HTG. John Clarke,
formerly the CEO of the Nuclear Decommissioning Authority (NDA),
also joined the Board as a non-executive director. Within the Group
structure, Colin Elcoate was confirmed as the Chief Commercial
Officer for Avingtrans.
The new divisional structure has driven other top management
changes, as follows:
- Mike Turmelle was promoted to Divisional Managing Director of the EPM division
- Austen Adams continued as Divisional Managing Director of the expanded PSRE division
- Austen Adams is also Acting Divisional Managing Director of
the MII division and will continue in this role until the medical
businesses fully separate from our energy assets and a full senior
team is in place.
The management teams in the three divisions continue to be
strengthened, with a number key appointments being made in the year
and with emphasis on the importance of the aftermarket
opportunities. Skills availability is always challenging, but we do
not expect to be unduly constrained by shortages. Avingtrans
continues to invest significant effort in developing skills, both
through structured apprenticeship programmes and also graduate
development plans. The Group continues to be recognised nationally
for the strength of its apprenticeship and graduate training
schemes. Metalcraft recently won the top accolade for 'SME
Investment in Skills' at the SEMTA (Scientific, Engineering,
Manufacturing & Technology Alliance) 2018 Awards.
Our global workforce is now becoming more integrated and this
provides additional capability, capacity and innovative thinking
around the clock, to support to our global blue-chip customer
base.
Health, Safety and Environment (HSE)
The Group takes HSE matters and its related responsibilities
very seriously.
As regular acquirers of businesses, we find different levels of
capability and knowledge in different businesses. Often, a key
investment need in smaller acquisitions is to spread HSE best
practice from other Group businesses and bring local processes up
to required standards. Larger acquisitions like HTG have well
developed HSE practices and we seek to learn from these in other
business units.
Health and Safety incident reporting has improved across the
Group and incident trends have generally been improving over recent
years. Near miss reporting and knowledge exchange is also
positively encouraged, to facilitate learning and improvement. At
Board level, Les Thomas has HSE oversight and he conducts
inspections with local management as appropriate.
The Group's environmental policy is to ensure that we understand
and effectively manage the actual and potential environmental
impact of our activities. Our operations are conducted such that we
comply with all legal requirements relating to the environment in
all areas where we carry out our business.
During the period covered by this report, the Group has not
incurred any significant fines or penalties, or been investigated
for any significant breach of HSE regulations.
Social Responsibility
It is paramount that the Group maintains the highest ethical and
professional standards across all of its activities and that social
responsibility should be embedded in operations and decision
making. We understand the importance of managing the impact that
the business can have on employees, customers, suppliers and other
stakeholders. The impact is regularly reviewed to sustain
improvements, which in turn support the long-term performance of
the business.
Our focus is to embed the management of these areas into our
business operations, both managing risk and delivering
opportunities that can have a positive influence on our
business.
Employees
The Group places considerable value on the involvement of its
employees and has continued to keep them informed on matters
affecting them directly and on financial and broader economic
factors affecting the Group. The Group regularly reviews its
employment policies. The Group is committed to a global policy of
equality, providing a working environment that maintains a culture
of respect and reflects the diversity of our employees. We are
committed to offering equal opportunities to all people regardless
of their sex, nationality, ethnicity, language, age, status, sexual
orientation, religion or disability.
We believe that employees should be able to work safely in a
healthy workplace, without fear of any form of discrimination,
bullying or harassment. We believe that the Group should
demonstrate a fair gender mix across all levels of our business,
whilst recognising that the demographics of precision engineering
and manufacturing remain predominantly male, which is largely
beyond our control.
Ethical policy
The Group complies with the Bribery Act 2010. We do not tolerate
bribery, corruption or other unethical behaviour on the part of any
of our businesses or business partners in any part of the world.
Employee training has been completed in all areas of the business
to ensure that the Act is complied with.
Outlook
Avingtrans is a niche engineering market leader in the Energy
and Medical sectors. Recent acquisitions (particularly that of HTG)
will afford investors another opportunity to build enduring value
with us in a rich seam of engineering market niches. We will
continue to be frugal and seek to crystallise value and return
capital when the timing is right, as part of our successful PIE
strategy.
The Group is now focused on investing in its three new divisions
in the global energy and medical markets, to position them for
maximum shareholder value via eventual exits in the years to come.
To this end, it was essential that the integration and
restructuring following the acquisition of HTG was both quick and
clinical, allowing the management team to concentrate on profitable
future growth.
The energy divisions have a strong emphasis on both the nuclear
and off shore Oil & Gas markets, both of which are showing
signs of regeneration. The medical division continues to focus on
high integrity components and systems for leading medical,
industrial and scientific equipment manufacturers.
To drive short term profitability and market engagement, all
divisions have clear strategies to support end-user aftermarket
operations, whether by servicing their own equipment or that of
third parties, to capitalise on the continued drive for efficient,
reliable and safe facilities.
We are not unduly concerned by Brexit, since our direct EU
exposure is rather limited and we have taken some initial evasive
action in our supply chains, with likely further such actions to
follow, depending on the exact nature of the Brexit deal.
Similarly, US government tariff change risks have been largely
mitigated by an agile supply chain response and we will continue to
monitor this situation closely.
As markets continue to recover, M&A activity remains strong
and businesses like ours can command high valuations at the point
of disposal, as was perfectly exemplified by the Sigma sale
previously. At Avingtrans, we are confident about the current
strategic direction and potential future opportunities across our
markets and sphere of influence. We will continue to hone our
business by pinpointing specific additional acquisitions as the
opportunities arise, to invest and build businesses that we expect
to attract premium valuations.
Roger McDowell Steve McQuillan Stephen King
Chairman Chief Executive Officer Chief Financial Officer
2 October 2018 2 October 2018 2 October 2018
Consolidated Income Statement
for the year ended 31 May 2018 Note 2018 2017
GBP'000 GBP'000
Revenue 1 78,864 22,714
Cost of sales (58,787) (18,659)
--------- ---------
Gross profit 20,077 4,055
Distribution costs (4,050) (713)
Share based payment expense (69) (34)
Acquisition costs (1,567) (101)
Restructuring costs (1,699) (182)
Tender share buyback costs - (226)
Amortisation of intangibles from business combinations (3,303) -
Other administrative expenses (13,231) (3,265)
--------- ---------
Total administrative expenses (19,869) (3,808)
Operating loss 1 (3,842) (466)
Finance income 36 219
Finance costs (692) (38)
--------- ---------
Loss before taxation (4,498) (285)
Taxation 3 12 (11)
Loss for the financial year attributable to equity shareholders (4,486) (296)
========= =========
Loss per share:
From continuing operations
- Basic 4 (16.0)p (1.3)p
- Diluted 4 (16.0)p (1.3)p
========= =========
Consolidated statement of Comprehensive income
2018 2017
GBP'000 GBP'000
Loss for the year (4,486) (296)
Items that will not be subsequently be reclassified to profit or loss
Remeasurement of net defined benefit liability 71 -
Income tax relating to items not reclassified (14) -
Items that may/will subsequently be reclassified to profit or loss
Exchange differences on translation of foreign operations (137) 10
Total comprehensive income for the year attributable to equity shareholders (4,566) 31,732
======== ========
Consolidated statement of changes in equity
at 31 May 2018
Capital
Share redemp- Trans-
premium tion Merger lation Other Invest-ment Retained
Share capital account reserve reserve reserve reserves in own shares earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
At 1 June 2016 1,387 10,903 814 - (8) 180 (1,000) 52,477 64,753
Ordinary
shares issued 56 1,868 - - - - - - 1,924
Dividends paid - - - - - - - (886) (886)
Investment in
own shares - - - - - - (1,250) - (1,250)
Tender share
buyback (485) - 485 - - - - (19,383) (19,383)
Share-based
payments - - - - - - - 34 34
------------- -------- -------- -------- -------- --------- -------------- ---------- --------
Transactions
with owners (429) 1,868 485 - - - (1,250) (20,235) (19,561)
Loss for the
year - - - - - - - (296) (296)
Other
comprehensive
income
Exchange gain - - - - 10 - - - 10
------------- -------- -------- -------- -------- --------- -------------- ---------- --------
Total
comprehensive
income for
the year - - - - 10 - - (296) (286)
------------- -------- -------- -------- -------- --------- -------------- ---------- --------
Balance at 31
May 2017 958 12,771 1,299 - 2 180 (2,250) 31,946 44,906
============= ======== ======== ======== ======== ========= ============== ========== ========
At 1 June 2017 958 12,771 1,299 - 2 180 (2,250) 31,946 44,906
Ordinary
shares issued 595 614 - 28,949 - - - - 30,158
Dividends paid - - - - - - - (906) (906)
Investment in
own shares - - - - - - (585) - (585)
Share-based
payments - - - - - - - 69 69
------------- -------- -------- -------- -------- --------- -------------- ---------- --------
Transactions
with owners 595 614 - 28,949 - - (585) (837) 28,736
Loss for the
year - - - - - - - (4,486) (4,486)
Other
comprehensive
income
Actuarial gain
for the year
on pension
scheme - - - - - - - 71 71
Deferred tax
on actuarial
movement on
pension
scheme - - - - - - - (14) (14)
Exchange gain - - - - (137) - - - (137)
------------- -------- -------- -------- -------- --------- -------------- ---------- --------
Total
comprehensive
income for
the year - - - - (137) - - (4,429) (4,566)
------------- -------- -------- -------- -------- --------- -------------- ---------- --------
Balance at 31
May 2018 1,553 13,385 1,299 28,949 (135) 180 (2,835) 26,680 69,076
============= ======== ======== ======== ======== ========= ============== ========== ========
Consolidated Balance Sheet
at 31 May 2018 2018 2017
GBP'000 GBP'000
Non current assets
Goodwill 23,369 5,198
Other intangible assets 15,612 1,442
Property, plant and equipment 27,595 4,850
Deferred tax 1,454 -
Pension and other employee obligations 1,590 -
---------- ---------
69,620 11,490
Current assets
Inventories 10,341 5,618
Trade and other receivables : amounts falling due within one year 34,606 9,038
Trade and other receivables : amounts falling due after one year - 580
Current tax asset 608 52
Cash and cash equivalents 6,574 27,703
---------- ---------
52,129 42,991
Total assets 121,749 54,481
========== =========
Current liabilities
Trade and other payables (26,179) (7,870)
Obligations under finance leases (1,179) (142)
Borrowings (6,719) (179)
Current tax liabilities (15) -
Provisions (6,135) -
Derivatives (127) -
Total current liabilities (40,354) (8,191)
========== =========
Non current liabilities
Borrowings (4,435) (896)
Obligations under finance leases (1,375) (37)
Deferred tax (2,914) (195)
Contingent consideration (256) (256)
Other creditors (3,339) -
---------- ---------
Total non-current liabilities (12,319) (1,384)
---------- ---------
Total liabilities (52,673) (9,575)
========== =========
Net assets 69,076 44,906
========== =========
Equity
Share capital 1,553 958
Share premium account 13,385 12,771
Capital redemption reserve 1,299 1,299
Translation reserve (135) 2
Merger reserve 28,949 -
Other reserves 180 180
Investment in own shares (2,835) (2,250)
Retained earnings 26,680 31,946
Total equity attributable to equity holders of the parent 69,076 44,906
========== =========
Consolidated Cash Flow Statement
for the year ended 31 May 2018 Note 2018 2017
GBP'000 GBP'000
Operating activities
Cash flows from operating activities (6,142) (3,221)
Finance costs paid (363) (38)
Income tax paid (212) (1)
Contributions to defined benefit plan (175) -
---------- ----------
Net cash outflow from operating activities (6,892) (3,260)
---------- ----------
Investing activities
Acquisition of subsidiary undertakings , net of cash acquired 5 (11,896) (585)
Finance income 13 219
Purchase of intangible assets (712) (626)
Purchase of property, plant and equipment (2,654) (484)
Proceeds from sale of property, plant and equipment - 13
---------- ----------
Net cash used by investing activities (15,249) (1,463)
Financing activities
Equity dividends paid (906) (886)
Repayments of bank loans (3,483) (334)
Repayments of obligations under finance leases (1,025) (292)
Proceeds from issue of ordinary shares 47 612
Purchase of shares - tender buyback - (19,383)
Proceeds from borrowings 6,289 -
---------- ----------
Net cash inflow/(outflow) from financing activities 922 (20,283)
Net decrease in cash and cash equivalents (21,219) (25,006)
Cash and cash equivalents at beginning of year 27,703 52,923
Effect of foreign exchange rate changes on cash 81 (214)
---------- ----------
Cash and cash equivalents at end of year 6,565 27,703
---------- ----------
Cash flows from operating activities:
for the year ended 31 May 2018
2018 2017
GBP'000 GBP'000
Continuing operations
Loss before income tax from continuing operations (4,498) (285)
Adjustments for:
Depreciation 2,532 525
Amortisation of intangible assets 374 120
Amortisation of intangibles from business combinations 3,303 -
Gain on disposal of property, plant and equipment - (13)
Finance income (36) (219)
Finance expenses 692 38
Share based payment charge 69 34
Changes in working capital
Increase in inventories 4,144 (2,482)
Increase trade and other receivables (8,618) (1,654)
Increase in trade and other payables (3,088) 711
Increase in provisions (1,039) -
Other non cash changes 23 4
Cashflows from operating activities (6,142) (3,221)
======= =======
Notes to the Preliminary Statement
31 May 2018
1 Segmental analysis
Energy Energy Medical Unallocated
Year ended 31 May 2018 EPM PSRE MII central items Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Original Equipment 15,194 20,096 10,410 - 45,700
After Market 21,581 11,583 - - 33,164
---------- ---------- -------------- --------------- -------------------
Revenue 36,775 31,679 10,410 - 78,864
========== ========== ============== =============== ===================
Operating profit/(loss) (1,532) 425 (109) (2,626) (3,842)
Net finance costs (656)
Taxation 12
-------------------
Loss after tax from continuing operations (4,486)
===================
Segment non-current assets 37,636 27,174 4,810 - 69,620
Segment current assets 23,484 22,322 3,645 2,678 52,129
---------- ---------- -------------- --------------- -------------------
Segment liabilities (28,632) (15,933) (2,572) (5,536) (52,673)
---------- ---------- -------------- --------------- -------------------
Net assets 32,488 33,563 5,883 (2,858) 69,076
========== ========== ============== =============== ===================
Non-current asset additions
Intangible assets 10 255 447 - 712
Tangible assets 1,438 854 362 - 2,654
---------- ---------- -------------- --------------- -------------------
1,448 1,109 809 - 3,366
========== ========== ============== =============== ===================
Energy-PSRE results include the acquisition of Ormandy and part of HTG acquisition which contributed
GBP1,859,000 and GBP15,023,000 to Group revenue respectively and GBP82,000 and GBP390,000
loss after tax respectively (note 5). Energy-EPM is all part of the HTG acquisition (note
5).
Energy Medical Unallocated
Year ended 31 May 2017 PSRE MII central items Total
GBP'000 GBP'000 GBP'000 GBP'000
Original Equipment 301 - - 301
After Market 12,309 - - 12,309
---------- ---------- -------------- ------------------------------------
Revenue 12,610 10,104 - 22,714
========== ========== ============== ====================================
Operating profit/(loss) 456 428 (1,350) (466)
Net finance costs 181
Taxation (11)
------------------------------------
Loss after tax from continuing
operations (296)
Segment non-current assets 7,482 4,008 - 11,490
Segment current assets 10,314 6,102 26,575 42,991
---------- ---------- -------------- ------------------------------------
Segment liabilities (4,158) (2,241) (3,176) (9,575)
---------- ---------- -------------- ------------------------------------
Net assets 13,638 7,869 23,399 44,906
========== ========== ============== ====================================
Non-current asset additions
Intangible assets 587 39 - 626
Tangible assets 316 168 - 484
---------- ---------- -------------- ------------------------------------
903 207 - 1,110
========== ========== ============== ====================================
Notes to the Preliminary Statement (continued)
31 May 2018
Geographical
2018 2017 2018 2017
Non-current Non-current
Revenue Revenue assets Assets
GBP'000 GBP'000 GBP'000 GBP'000
United Kingdom 31,970 18,635 49,981 10,111
Europe (excl UK) 7,197 785 - -
United States of America 14,210 5 17,792 -
Africa & Middle East 2,766 1,846 - -
Americas & Caribbean (excl US) 1,190 - - -
China 5,286 1,416 1,841 1,379
Asia Pacific (excl.China) 16,117 - 6 -
Rest of World 128 27 - -
78,864 22,714 69,920 11,490
========= ======= =========== ===========
The Group had Medical revenue of GBPnil (2017: GBP7,229,000)
with single external customers under common control, which each
represent more than 10% of the Group's revenue.
2 Adjusted Earnings before interest, tax, depreciation and amortisation
2018 2017
GBP'000 GBP'000
Loss before tax from continuing operations (4,498) (285)
Share based payment expense 69 34
Acquisition costs 1,567 101
Restructuring costs 1,699 182
Tender share buyback costs - 226
Loss on derivatives 172 -
Unwinding of discounting on dilapidation provision 62 -
Amortisation of intangibles from business combinations 3,303 -
------- -------
Adjusted profit before tax 2,374 258
Finance income (36) (219)
Finance cost 692 38
Loss on derivatives/unwinding of discounting on dilapidation provision (234) -
------- -------
Adjusted profit/ (loss) before interest, tax and amortisation from business combinations ('EBITA') 2,796 77
Depreciation 2,532 525
Amortisation of other intangible assets 375 120
Adjusted Earnings before interest, tax, depreciation and amortisation ('EBITDA') 5,703 722
======= =======
The Directors believe that the above adjusted earnings are a
more appropriate reflection of the Group performance.
3 Taxation
2018 2017
GBP'000 GBP'000
Current tax 1,156 (58)
Deferred tax (1,168) 69
(12) 11
======== ========
Notes to the Preliminary Statement (continued)
31 May 2018
4 Earnings per ordinary share
2018 2017
Number Number
Weighted average number of shares - basic 27,952,066 22,295,083
Share option adjustment 360,448 288,451
Weighted average number of shares - diluted 28,312,514 22,583,534
========== ==========
2018 2017
GBP'000 GBP'000
Loss from continuing operations (4,486) (296)
Share-based payments 69 34
Acquisition costs 1,567 101
Restructuring costs 1,699 182
Tender share buyback costs - 226
Loss on derivatives 172 -
Unwinding of discounting on dilapidation provision 62 -
Amortisation of intangibles from business combinations 3,303 -
Adjusted earnings attributable to shareholders 2,386 247
========== ==========
Basic loss per share (16.0)p (1.3)p
Adjusted basic earnings per share 8.5p 1.1p
Diluted loss per share (16.0)p (1.3)p
Adjusted diluted earnings per share 8.4p 1.1p
The Directors believe that the above adjusted earnings per share
calculation for continuing operations is a more appropriate
reflection of the Group's underlying performance.
The basic loss per share attributable to ordinary shareholders
and diluted loss per share for the year ended 31 May 2019 are
identical because the dilutive impact of an exercise of share
options would have the effect of reducing the loss per share and
is, therefore, is not a dilution under the terms of IAS33.
Notes to the Preliminary Statement (continued)
31 May 2018
5 Acquisitions
Business combination - Hayward Tyler Group plc
On 1 September 2017 the Group acquired 100 percent of the issued
share capital of Hayward Tyler Group plc ('HTG"'). The acquisition
was made to enhance the Group's position in the Energy division.
The provisional fair value of net assets acquired at the date of
acquisition were as follows:
Fair value of assets and liabilities acquired GBP'000
Other intangible assets 837
Property, plant and equipment 22,846
Deferred tax 392
Pension and other employee obligations 1,320
Inventories 8,592
Trade and other receivables 17,095
Cash and cash equivalents 739
Current tax asset 1,251
Derivatives 45
Trade and other payables (21,110)
Obligations under finance leases (3,307)
Borrowings (7,357)
Provisions (7,175)
Other creditors (3,545)
--------
Net assets 10,623
Business combinations intangibles assets identified 16,082
Deferred tax on intangibles identified (2,850)
Goodwill 18,171
42,026
========
Fair value of consideration transferred:
Cash 12,500
Repayment of loans 29,526
--------
Consideration 42,026
Cash acquired (739)
Loans repaid 12,500
Acquisition costs charged to expenses 1,469
--------
Net cash paid relating to the acquisition 13,230
========
The GBP12,500,000 loans repaid were subject to change of control
provisions. Acquisition costs arising from this transaction of
GBP1,469,000 have been included in administration expenses included
in overheads before operating profit.
The impact of the HTG acquisition on the Consolidated
income statement is as follows: GBP'000
Revenue 51,798
Gross profit 15,954
Overheads (12,954)
Restructuring costs (1,622)
Amortisation of intangibles from business combinations (3,300)
---------
Operating loss (1,922)
Finance income 24
Finance costs (959)
---------
Loss before taxation (2,857)
Taxation (668)
---------
Overall effect on the Consolidated income statement (3,525)
=========
Notes to the Preliminary Statement (continued)
31 May 2018
5 Acquisitions (continued)
Business combination - Hayward Tyler Group plc (continued)
Since acquisition HTG contributed the following to the Group's cashflows: 2018
GBP'000
Operating cashflows (4,438)
Investing activities (1,844)
Financing activities 2,011
Business combination - Ormandy Group
On 19 February 2018 the Group acquired certain of the assets and
IP of the Ormandy Group. The acquisition was made to enhance the
Group's position in the PSRE - Energy division. The net assets at
the date of acquisition were as follows:
Fair value of assets and liabilities acquired GBP'000
Property, plant and equipment 10
Inventories 268
Trade and other payables (193)
-------
Net Assets 85
Intangibles assets identified -
Goodwill & IP 50
135
=======
Fair value of consideration transferred:
Cash 135
-------
Consideration 135
Acquisition costs charged to expenses 99
-------
Net cash paid relating to the acquisition 234
=======
Management did not identify any further intangible assets on
acquisition of this business due to its distressed state.
Acquisition costs arising from this transaction of GBP99,000
have been included in administration expenses included in overheads
before operating profit.
The impact of the Ormandy acquisition on the Consolidated
income statement is as follows: GBP'000
Revenue 1,859
Gross profit 115
Overheads (194)
Restructuring costs -
Amortisation of intangibles from business combinations (3)
--------
Operating loss (82)
Finance income & costs -
--------
Loss before taxation (82)
Taxation (16)
--------
Overall effect on the Consolidated income statement (66)
Since acquisition Ormandy contributed the following to the Group's cashflows: 2018
GBP'000
Operating cashflows (349)
Investing activities (135)
Notes to the Preliminary Statement (continued)
31 May 2018
6 Net (debt)/cash and gearing
The gearing ratio at the year-end is as follows: 2018 2017
GBP'000 GBP'000
Debt (13,708) (1,254)
Cash and cash equivalents 6,565 27,703
---------- ---------
Net (debt)/cash (7,143) 26,449
Equity 69,076 44,906
---------- ---------
Net (debt)/cash to equity ratio (10.3)% 58.9%
========== =========
7 Preliminary statement and basis of preparation
This preliminary statement, which has been agreed with the
auditors, was approved by the Board on 2 October 2018. It is not
the Group's statutory accounts within the meaning of Section 434 of
the Companies Act 2006.
The statutory accounts for the two years ended 31 May 2018 and
2017 received audit reports which were unqualified and did not
contain statements under s498(2) or (3) of the Companies Act 2006.
The statutory accounts for the year ended 31 May 2017 have been
delivered to the Registrar of Companies but the 31 May 2018
accounts have not yet been filed.
The Company's financial statements have been prepared and
approved by the directors in accordance with International
Financial Reporting Standards (IFRSs) as adopted by the European
Union and those parts of the Companies Act 2006 that apply to
companies reporting under IFRS. The principal accounting policies
adopted by the company, which remain unchanged, are set out in the
statutory financial statements for the year ended 31 May 2018.
8 Annual report and Accounts
The Report and Accounts for the year ended 31 May 2018 will be
available on the Group's website www.avingtrans.plc.uk on or around
8 October 2017. Further copies will be available from the
Avingtrans' registered office:
Chatteris Business Park, Chatteris, Cambridgeshire PE16 6SA.
9 Annual General Meeting
The Annual General Meeting of the Group will be held at
Shakespeare Martineau LLP, No1 Colmore Square, Birmingham, B4 6AA
on 15 November 2018 at 11:00am
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
FR MTBATMBJMBPP
(END) Dow Jones Newswires
October 03, 2018 02:00 ET (06:00 GMT)
Avingtrans (LSE:AVG)
Historical Stock Chart
From Apr 2024 to May 2024
Avingtrans (LSE:AVG)
Historical Stock Chart
From May 2023 to May 2024